Health Services Costs and Their Determinants in Women with Fibromyalgia
JOHN R. PENROD, SASHA BERNATSKY, VIVIANE ADAM, MURRAY BARON, NATALIE DAYAN, and PATRICIA L. DOBKIN
Methods. Subjects (n = 180 women) completed a health resource questionnaire as well as measures of pain, psychological distress, comorbidity, and disability. Unit costs for resources were obtained from government, hospital, laboratory, and professional association sources. Regression modeling for 6-month direct cost included age, disability, comorbidity, pain intensity, psychological distress, education, and work status.
Results. The average 6-month direct cost was $CDN 2298 (SD 2303). The largest components were medications ($CDN 758; SD 654), complementary and alternative medicine (CAM; $CDN 398; SD 776), and diagnostic tests ($CDN 356; SD 580). Our most conservative estimate of average 6-month indirect cost was $CDN 5035 (SD 7439). Comorbidity and FM disability were statistically significant contributors to direct costs in the multivariate analysis. Costs increased by approximately 20% with each additional comorbid condition.
Conclusion. Women with FM are high consumers of both conventional and CAM services. Our estimates of costs exceed those from most other studies; this may be due to our inclusion of a broader set of health services, medications, and indirect costs. Although in univariate analyses the number of comorbidities and indices of the effect of FM, psychological distress, and pain intensity were associated with higher direct cost, in a multiple regression analysis, only the measure of FM disability and the number of comorbidities were significant direct-cost determinants. FM also imposes important indirect costs, which were nearly 70% of the economic burden. (J Rheumatol 2004;31:1391-8)
Key Indexing Terms:
From the Division of Clinical Epidemiology, McGill University Health Centre; Department of Medicine, McGill University; and Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Supported by The Arthritis Society.
J.R. Penrod, PhD, Assistant Professor; S. Bernatsky, MD, MSc, Research Fellow; V. Adam, MSc; N. Dayan, BSc, Division of Clinical Epidemiology, McGill University Health Centre; M. Baron, MD, Jewish General Hospital; P.L. Dobkin, PhD, Associate Professor, Department of Medicine, McGill University.
Address reprint requests to Dr. P. Dobkin, Division of Clinical Epidemiology, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada. E-mail: email@example.com
Submitted March 6, 2003; revision accepted December 24, 2003.